{
    "clinical_study": {
        "@rank": "84076", 
        "arm_group": [
            {
                "arm_group_label": "VAY736", 
                "arm_group_type": "Experimental", 
                "description": "Intravenous infusion of VAY736"
            }, 
            {
                "arm_group_label": "Placebo to VAY736", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Matching placebo (infusion bag) administered intravenously. Placebo randomized patients will be offered optional VAY736 administration after week 16"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this study is to determine if a monoclonal antibody VAY736 can reduce disease\n      activity in relapsing-remitting multiple sclerosis (RRMS) as compared to placebo. The study\n      will also provide the first safety and tolerability information for VAY736 in RRMS patients."
        }, 
        "brief_title": "A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Relapse Remitting Multiple Sclerosis", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Sclerosis", 
                "Sclerosis", 
                "Multiple Sclerosis, Relapsing-Remitting"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        18 Years to 55 Years Male and Female\n\n          -  Diagnosis of MS as defined by the 2010 revised McDonald criteria (Polman, et.\n             al2011).\n\n               -  A relapsing-remitting course of disease with:\n\n               -  at least 1 documented relapse during the previous 12 months (but not within 30\n                  days prior to randomization), or\n\n               -  a positive Gd-enhancing lesion on brain MRI scan at screening.\n\n               -  An Expanded Disability Status Scale (EDSS) score of 0-5.0 inclusive at\n                  screening.\n\n               -  No evidence of a relapse within 30 days prior to randomization.\n\n        Exclusion Criteria:\n\n          -  \u2022 A manifestation of another type of MS other than RRMS.\n\n               -  Findings on screening or baseline brain MRI inconsistent with the diagnosis of\n                  MS.\n\n               -  History of chronic disease of the immune system other than MS, or a known\n                  immunodeficiency syndrome\n\n               -  Women of child-bearing potential, defined as all women physiologically capable\n                  of becoming pregnant, unless they are using highly effective methods of\n                  contraception during dosing and for 4 months following completion of the study.\n\n               -  Unable to undergo MRI scans due to inter-alia, claustrophobia, incompatible\n                  cardiac pacemakers, ferromagnetic intracranial aneurysm clips,  certain cochlear\n                   implants, and certain other ferromagnetic foreign bodies (e.g. tattoos\n                  containing metal) or electronic devices, or metallic implants incompatible with\n                  MRI.\n\n               -  Unable to receive gadolinium-based MRI contrast agents due to a history of\n                  hypersensitivity to gadolinium-based contrast agents, renal insufficiency or\n                  impairment.\n\n        Other protocol-defined inclusion/exclusion criteria may apply"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "96", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 14, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02038049", 
            "org_study_id": "CVAY736X2202"
        }, 
        "intervention": [
            {
                "arm_group_label": "VAY736", 
                "intervention_name": "VAY736", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo to VAY736", 
                "description": "Placebo to VAY736", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Multiple Sclerosis, Relapsing-Remitting Multiple Sclerosis, Magnetic Resonance Imaging, VAY736, monoclonal antibody, gadolinium [Gd]-enhancing lesions, B-Cell", 
        "lastchanged_date": "January 20, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Long Beach", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90806"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92103"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fort Wayne", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46845"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dayton", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45408"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brno", 
                        "country": "Czech Republic", 
                        "zip": "656 91"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hradec Kralove", 
                        "country": "Czech Republic", 
                        "zip": "501 03"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ostrava-Poruba", 
                        "country": "Czech Republic", 
                        "zip": "708 52"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "10117"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bochum", 
                        "country": "Germany", 
                        "zip": "44791"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Heidelberg", 
                        "country": "Germany", 
                        "zip": "69120"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "M\u00fcnchen", 
                        "country": "Germany", 
                        "zip": "81377"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "T\u00fcbingen", 
                        "country": "Germany", 
                        "zip": "72076"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Smolensk", 
                        "country": "Russian Federation", 
                        "state": "Russia", 
                        "zip": "214019"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation", 
                        "zip": "129128"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nizhny Novgorod", 
                        "country": "Russian Federation", 
                        "zip": "603155"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sestroreck", 
                        "country": "Russian Federation", 
                        "zip": "197706"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tver", 
                        "country": "Russian Federation", 
                        "zip": "170036"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kharkiv", 
                        "country": "Ukraine", 
                        "zip": "61068"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kiev", 
                        "country": "Ukraine"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lviv", 
                        "country": "Ukraine", 
                        "zip": "79010"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Odesa", 
                        "country": "Ukraine", 
                        "zip": "65117"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Zaporozhye", 
                        "country": "Ukraine", 
                        "zip": "69600"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Czech Republic", 
                "Germany", 
                "Russian Federation", 
                "Ukraine"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Partially Blind, Placebo-controlled, Proof-of-concept Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity as Measured by Brain MRI Scans in Patients With Relapsing-remitting Multiple Sclerosis", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "1-888-669-6682"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone_ext": "+41613241111"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Germany: Paul-Ehrlich-Institut", 
                "United States: Food and Drug Administration", 
                "Russia: Pharmacological Committee, Ministry of Health", 
                "Czech Republic: State Institute for Drug Control", 
                "Italy: Ministry of Health", 
                "Poland: Ministry of Health", 
                "Ukraine: Ministry of Health"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary objective is to evaluate the effect of VAY736 on the cumulative number of new Gd-enhancing brain lesions in RRMS patient population at weeks 8, 12 and 16.\nIt will be analyzed by means of a negative binomial regression model (with factor \"treatment\") adjusting for baseline lesion count and number of MRI scans.", 
            "measure": "Cumulative number of new Gd-enhancing lesions", 
            "safety_issue": "No", 
            "time_frame": "8, 12, 16 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02038049"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "It will be compared separately at each week between treatment groups using a negative binomial regression model adjusting for baseline lesion count and number of MRI scans.", 
                "measure": "Number of new and cumulative number of new T1-weighted Gd-enhancing lesions at weeks 4, 8, 12 and 16", 
                "safety_issue": "No", 
                "time_frame": "4, 8, 12, 16 weeks"
            }, 
            {
                "description": "It will be compared separately at each week between treatment groups using a negative binomial regression model adjusting for baseline lesion count and number of MRI scans", 
                "measure": "Number of all T1-weighted Gd-enhancing lesions at weeks 4, 8, 12 and 16", 
                "safety_issue": "No", 
                "time_frame": "4, 8, 12, 16 weeks"
            }, 
            {
                "description": "It will be compared between treatment groups using a negative binomial regression model adjusting for baseline lesion count and number of MRI scans.", 
                "measure": "Cumulative number of new or enlarging T2-weighted Gd-enhancing lesions at weeks 4, 8, 12 and 16", 
                "safety_issue": "No", 
                "time_frame": "4, 8, 12, 16 weeks"
            }, 
            {
                "description": "Change from baseline will be analyzed by ANCOVA separately at each week", 
                "measure": "T2 burden of disease (total volume of T2-weighted lesions) at weeks 4, 8, 12 and 16.", 
                "safety_issue": "No", 
                "time_frame": "4, 8, 12, 16 weeks"
            }, 
            {
                "description": "At each week, the proportion between treatment groups will be compared using a logistic regression model adjusting for baseline lesion count.", 
                "measure": "Proportion of subjects without any new MRI disease activity at weeks 4, 8, 12 and 16.", 
                "safety_issue": "No", 
                "time_frame": "4, 8, 12, 16 weeks"
            }, 
            {
                "description": "It will be compared using a negative binomial regression adjusting for baseline number of relapses in previous 2 years and log (time on study in years) as the offset variable.", 
                "measure": "The number of confirmed relapses at week 16.", 
                "safety_issue": "No", 
                "time_frame": "16 Weeks"
            }, 
            {
                "description": "It will be compared between treatment groups using a logistic regression model adjusting for baseline number of relapses in previous 2 years.", 
                "measure": "Proportion of relapse-free patients over the 16 weeks of the treatment period.", 
                "safety_issue": "No", 
                "time_frame": "16 weeks"
            }, 
            {
                "description": "Summarized statistics on adverse events will be reported under categories such as total adverse events, serious adverse events and death", 
                "measure": "Number of patients with adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Estimated mean 24 weeks"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}